[Expression of CD10 and renal cell carcinoma marker in clear cell renal cell carcinoma: analysis on tissue arrays]. / Expresión de CD10 y del marcador de carcinoma renal en el carcinoma renal de células claras: análisis en matrices tisulares.

OBJECTIVES: CD10 and renal cell carcinoma (RCC) marker antibodies react against proteins of the epithelium of the renal proximal tubule, being expressed by renal cell carcinomas. The frequence and pattern of expression of both markers are analysed in a series of clear cell renal cell carcinomas. METHOD: Two tissue arrays were used, which were composed of cylinders obtained with a 16G needle from 40 paraffin blocks that corresponded to clear cell renal cell carcinomas. The labeled streptavidin-biotin technique was performed (LSAB2, Dako) using CD10 and RCC monoclonal antibodies (Novocastra), testing different antigen retrieval methods for RCC. Immunoreactivity was evaluated as + (isolated cells or focal staining); ++ (moderate) and +++ (extense). RESULTS: Thirty cases (75%) were positive for CD10: 12 +; 5 ++ and 13 +++. The best antigen retrieval method for RCC was a double enzyme digestion (trypsin + protease). Twenty cases (50%) were positive for RCC: 7 +; 5 ++ and 8 +++. Four cases out of the 20 immunoreactive for RCC were negative for CD10. The 16 remaining cases also expressed CD10. CONCLUSIONS: CD10 and RCC are often expressed by clear cell renal cell carcinomas, and they may be useful markers to suggest a renal origin of carcinomas. RCC is less sensitive than CD10. Staining for both of them is usually focal, and thus sensitivity of these techniques decreases when small samples are investigated, such as tissue arrays. The antigen retrieval method is essential for RCC immunohistochemical detection, obtaining the best results with the use of proteolytic enzymes.

Expresión de CD10 y del marcador de carcinoma renal en el carcinoma renal de células claras: análisis en matrices tisulares / Expression of CD10 and renal cell carcinoma marker in clear cell renal cell carcinoma: analysis on tissue arrays

Objetivos: Los anticuerpos CD10 y marcador de carcinoma renal (MCR) reaccionan frente a proteínas del epitelio normal del túbulo contorneado proximal, expresándose por tanto en los carcinomas de células renales. Se analizan la frecuencia y el patrón de expresión de ambos marcadores inmunohistoquímicos en una serie de carcinomas renales de células claras. Método: Se han utilizado dos matrices tisulares (“tissue arrays”) constituidas por cilindros obtenidos con aguja 16G de 40 bloques de parafina correspondientes a carcinomas renales de células claras. Se realizó técnica de estreptavidina marcada - biotina (LSAB2, Dako) con anticuerpos monoclonales CD10 y MCR (Novocastra), ensayándose para este último distintos métodos de recuperación antigénica. Se valoró la positividad como + (aislada o muy focal); ++ (moderada) y +++ (extensa). Resultados: Con CD10 fueron positivos 30 casos (75%): 12 +; 5 ++ y 13 +++. Con respecto a MCR, el mejor método de desenmascaramiento antigénico fue un doble tratamiento enzimático (tripsina + proteasa). Se encontró positividad para MCR en 20 casos (50%): 7+; 5 ++ y 8 +++. De los 20 casos positivos para MCR, cuatro habían sido negativos para CD10. Los otros 16 expresaban también CD10. Conclusiones: CD10 y MCR se expresan con frecuencia en los carcinomas renales de células claras, por lo que pueden ser marcadores útiles para sugerir en un carcinoma un origen renal. MCR presenta menor sensibilidad que CD10. Al ser la expresión de ambos habitualmente focal, la sensibilidad de estas técnicas es menor cuando se utilizan muestras pequeñas, como son las matrices tisulares. En la técnica IHQ para MCR resulta crucial el método de desenmascaramiento antigénico, obteniéndose los mejores resultados con el uso de enzimas proteolíticos

Objectives: CD10 and renal cell carcinoma (RCC) marker antibodies react against proteins of the epithelium of the renal proximal tubule, being expressed by renal cell carcinomas. The frequence and pattern of expression of both markers are analysed in a series of clear cell renal cell carcinomas. Method: Two tissue arrays were used, which were composed of cylinders obtained with a 16G needle from 40 paraffin blocks that corresponded to clear cell renal cell carcinomas. The labeled streptavidin-biotin technique was performed (LSAB2, Dako) using CD10 and RCC monoclonal antibodies (Novocastra), testing different antigen retrieval methods for RCC. Immunoreactivity was evaluated as + (isolated cells or focal staining); ++ (moderate) and +++ (extense). Results: Thirty cases (75%) were positive for CD10: 12 +; 5 ++ and 13 +++. The best antigen retrieval method for RCC was a double enzyme digestion (trypsin + protease). Twenty cases (50%) were positive for RCC: 7 +; 5 ++ and 8 +++. Four cases out of the 20 immunoreactive for RCC were negative for CD10. The 16 remaining cases also expressed CD10. Conclusions: CD10 and RCC are often expressed by clear cell renal cell carcinomas, and they may be useful markers to suggest a renal origin of carcinomas. RCC is less sensitive than CD10. Staining for both of them is usually focal, and thus sensitivity of these techniques decreases when small samples are investigated, such as tissue arrays. The antigen retrieval method is essential for RCC immunohistochemical detection, obtaining the best results with the use of proteolytic enzymes

[Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma]. / Estudio de la expresión de cerbB-2 en el adenocarcinoma de próstata.

OBJECTIVES: Our aim is to determine the expression of the cerbB-2 oncoprotein in prostate cancers using an immunohistochemistry staining and to compare these results with several clinical and histological prognostic factors. METHODS: An immunohistochemical staining using the cerbB-2 monoclonal antibody (Dako) was performed in 32 radical prostatectomy specimens diagnosed of adenocarcinoma. The intensity of cerbB-2 expression was evaluated with a scale that variated from 0 (no staining) to 3+ (strong complete membrane staining) according to published guidelines. Association of cerbB-2 index immunoreactivity with clinical and histological prognostic factors was examined. RESULTS: Definite positive membranous staining was detected in 14 of 32 neoplastic cases (44%). Such overexpression was correlated with higher Gleason grade (p=0.04) and higher stage of disease (p=0.038). CONCLUSIONS: 1) This study shows that 44% of all prostate cancer express the cerbB-2 oncoprotein with immunohistochemical technique. 2) These findings suggest that is necessary to standardize the immunohistochemical staining procedure with cerbB-2 in prostate adenocarcinoma. 3) The level of cerbB-2 expression was correlated with Gleason grade and clinical stage.

Estudio de la expresión de cerbB-2 en el adenocarcinoma de prostata / Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma

Objetivos: Determinar la expresión de la oncoproteína cerbB-2 en carcinomas de próstata con técnicas de inmunohistoquímica de próstata y comparar estos resultados con diversos factores pronósticos clínicos e histológicos. Material y métodos: Se realizó tinción inmunohistoquímica con el anticuerpo cerbB-2 (DAKO) en 32 piezas de prostatectomia radical infiltradas por un adenocarcinoma. La expresión de cerbB-2 fue evaluada de 0 (no-tinción) a 3+ (tinción intensa y continua en la membrana celular) según protocolo. Se analizó la asociación estadística entre la expresión de cerbB-2 con algunos parámetros clínicos e histológicos. Resultados: Se demostró positividad de membrana en 14 de las 32 neoplasias evaluadas (44%). La sobreexpresión de cerbB-2 se correlacionó estadísticamente con el índice de Gleason (p=0.04) y estadio clínico (p=0.038). Conclusiones: 1) Nuestro estudio muestra que aproximadamente el 44% de los carcinomas prostáticos expresan cerbB-2 con técnicas de inmunohistoquímica. 2) Esta serie permite deducir la necesidad de estandarizar la técnica inmunohistoquímica de cerbB-2 en el adenocarcinoma prostático. 3) En nuestro trabajo existe asociación estadística significativa de la expresión de cerbB-2, según el método modificado, con el estadío clínico e índice de Gleason

Objectives: Our aim is to determine the expression of the cerbB-2 oncoprotein in prostate cancers using an immunohistochemistry staining and to compare these results with several clinical and histological prognostic factors. Methods: An immunohistochemical staining using the cerbB-2 monoclonal antibody (Dako) was performed in 32 radical prostatectomy specimens diagnosed of adenocarcinoma. The intensity of cerbB-2 expression was evaluated with a scale that variated from 0 (no staining) to 3+ (strong complete membrane staining) according to published guidelines. Association of cerbB-2 index immunoreactivity with clinical and histological prognostic factors was examined. Results: Definite positive membranous staining was detected in 14 of 32 neoplastic cases (44%). Such overexpression was correlated with higher Gleason grade (p=0.04) and higher stage of disease (p=0.038). Conclusions: 1) This study shows that 44% of all prostate cancer express the cerbB-2 oncoprotein with immunohistochemical technique. 2) These findings suggest that is necessary to standardize the immunohistochemical staining procedure with cerbB-2 in prostate adenocarcinoma. 3) The level of cerbB-2 expression was correlated with Gleason grade and clinical stage

[Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage]. / Estudio comparativo de la expresión de p53, Ki67, bcl-2 y CK20 en el carcinoma transicional superficial de vejiga: correlación con la recurrencia, grado histológico y estadio clínico.

OBJECTIVE: We examined the presence of p53, Ki-67, bcl-2 and CK20, as detected by immunohistochemistry, and correlated with the classic variables (grade, stage and recurrence). MATERIAL AND METHOD: The authors evaluated 57 superficial transitional cell carcinomas. Biopsy specimens examined included non recurrent transitional cell carcinomas (n = 36) and recurrent transitional cell carcinomas (n = 21). Association of bcl-2, p53, Ki-67 y CK20 index immunoreactivity with tumor grade, clinical stage and tumor recurrence was examined. RESULTS: Ki-67 and p53 expression were related to the degree of differentiation and recurrence of the disease. bcl-2 and CK20 were not correlated with grade, stage and recurrence of the disease. CONCLUSIONS: Positivity for Ki-67 and p53 increase with grade of the disease. P53 and Ki-67 are predictors of tumor recurrence for patients with superficial transitional cell carcinoma.

Estudio comparativo de la expresión de p53, Ki67, bcl-2 y CK20 en el carcinomatransicional superficial de vejiga: correlación con la recurrencia, grado histológicoy estadio clínico / Comparative analysis of p53, Ki-67, bcl-2 and CK20 expression in superficial transitional cell carcinoma of urinary bladder: correlation with recurrence, histological grade and clinical stage

OBJETIVO: Analizar la correlación entre la expresión de p53, Ki67, bcl-2 y CK20, detectadas por técnicas de inmunohistoquímica, con las variables pronósticas clásicas: grado histológico, estadio clínico y recurrencia del tumor. MATERIAL Y MÉTODOS: Estudiamos 57 biopsias de carcinomas transicionales superficiales de vejiga. Las biopsias valoradas correspondían a 36 y 21 carcinomas transicionales de vejiga no recidivantes y recidivantes, respectivamente. Determinados la correlación entre la expresión de p53, Ki-67, bcl-2 y CK20 con el estadio clínico, grado histológico y la recurrencia del tumor. RESULTADOS: Demostramos una correlación estadísticamente significativa entre la expresión de Ki-67 y p53 con el grado histológico y la recidiva del tumor. No demostramos asociación estadísticamente significativa entre la expresión de bcl-2 y CK20 con el grado histológico, estadio clínico y recurrencia del tumor. CONCLUSIONES: La expresión de p53 y Ki-67 aumenta conforme aumenta el grado histológico del tumor y permite predecir la recurrencia de los carcinomas transicionales superficiales de vejiga (AU)